Public Companies
The MindMed Chronicles: An Interview With Robert Barrow, the CEO of MindMed
The following is a continuation of all our recent MindMed coverage. Over the past few weeks, we published a few conversations with Jake Freeman. Click…
The following is a continuation of all our recent MindMed coverage.
Over the past few weeks, we published a few conversations with Jake Freeman.
Before that, it all began with a two-part interview with Dr. Scott Freeman in August.
A Conversation with the MindMed CEO, Robert Barrow
While we’ve had the pleasure of speaking with Freeman Captial on multiple occasions, we are just as excited to be joined by MindMed’s CEO, Robert Barrow, to help readers better understand their side of the story. This interview with Robert is only the beginning. We fully expect to have him back on again soon.
Stay Tuned for More
We expect to have Rob and others involved in this story back on to continue the narrative. Stick around for more interviews, in-depth analyses, and insights as the story progresses.
Follow the Psychedelic Invest YouTube Channel
As always, please like and subscribe to the Psychedelic Invest YouTube channel.
-
LSD1 week ago
The First Wave of Blotter Acid Inspired Trippy Psychedelic Art
-
Psilocybin1 week ago
Psychedelic Underground Celebrated in San Francisco on Bicycle Day Weekend
-
Psychedelics5 days ago
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
-
Psychedelics5 days ago
Cybin to Participate at the 27th Annual Milken Institute Global Conference
-
Psychedelics4 days ago
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Psychedelics4 days ago
Behold! A New Mushroom Emoji Has Arrived!
-
Psychedelics4 days ago
Behold! A New Mushroom Emoji Has Arrived!
-
Psychedelics4 days ago
Are ‘Ketamine Bros’ Ruining It for Everyone Else?